Agenus (AGEN) is a pharmaceutical company focused on immunotherapies. Its current lead candidates are balstilimab, which has the same target, PD-1, as Opdivo and Keytruda, and zalifrelimab, which has the same CTLA-4 target as Yervoy. Agenus can claim to have a larger cancer immunotherapy pipeline than any other pharmaceutical company. While risks of failure exist until the company can demonstrate Phase 3 or equivalent results acceptable to the FDA, I see Agenus as likely becoming vastly more valuable in this decade.
I covered zalifrelimab and balstilimab in Agenus Reveals Improved Cancer Immunotherapy Results